For IO tools, immune monitoring, cell therapy CDMO and translational service companies: pre-scheduled 1:1 meetings with the teams building next-generation immunotherapies, in Boston in June 2027.
Sponsor Boston 2027
Our sponsorship team replies within one working day.
Trusted by sponsors from our London 2026 launch edition




Our London 2026 sponsors came from five kinds of company, and the Biomarkers & CDx stream adds a sixth. If yours is on this list, the agenda is built around your buyers.
Biomarker testing, flow cytometry and assay services for clinical trials.
Who you meet: Translational medicine and clinical biomarker leads

In vivo models and antibody discovery for immuno-oncology pipelines.
Who you meet: Discovery, pharmacology and preclinical heads
Instruments, reagents and platforms for immune profiling and proteomics.
Who you meet: Immune monitoring and translational science teams

Functional and spatial readouts from patient tissue.
Who you meet: Pathology and biomarker discovery leads
Data, literature and analytics for R&D and competitive intelligence.
Who you meet: R&D strategy and data science teams
The Biomarkers & CDx stream covers CDx development, regulatory strategy and market access.
Who you meet: Pharma CDx, regulatory and medical diagnostics leads
Tell us which roles you need to meet and we will show you how the audience matches up.
Request the prospectusImmunoMark Boston is an immuno-oncology conference in Boston for companies that sell into IO programs: research tools, immune monitoring, cell therapy manufacturing and translational services. The East Coast launch edition runs in June 2027, with Stream 1 dedicated to Immuno-Oncology and a parallel Stream 2 on Biomarkers & Companion Diagnostics.
Boston and Cambridge are home to one of the world’s densest concentrations of biotech companies, academic medical centers and cancer research institutes. For an IO vendor, that means many of the program teams you want to reach are already a short trip from the venue. The question is not whether those buyers exist, but how to get twenty focused minutes with the right ones. That is what this event is built to do.
The format is the one proven at London 2026: keynotes, panels and case studies across two parallel streams, a drinks reception at the end of Day 1, and pre-scheduled 20-minute 1:1 meetings chosen from the full delegate list and profiles, which reach sponsors about 10 days before the event.
The Boston Stream 1 speaker panel spans discovery, translational, computational and regulatory roles. Each one weighs a vendor against a different question.
| Function on the Boston faculty | What that function looks for in an IO vendor |
|---|---|
| Scientific Director, Precision Medicine Oncology, AbbVie | Assays and immune profiling that can follow a molecule from first-in-human studies into patient selection |
| Associate Scientist, Obsidian Therapeutics | Analytical methods that characterize engineered cell products and track their persistence in patients |
| Computational Science Lead, Sanofi | Data quality, standardized outputs and pipelines that slot into existing analysis workflows |
| Director, Global Regulatory Affairs, Oncology, AstraZeneca | Validated methods and documentation that will hold up in an IND or a marketing application |
| Instructor in Medical Oncology, Dana-Farber Cancer Institute | Clinical feasibility: sample logistics, turnaround and what a trial site can realistically support |
The faculty shows which functions will be in the room; it is not a list of guaranteed meetings. Your 1:1s are chosen from the full delegate list, so you can target the same functions at every company that comes. The Boston agenda’s audience profile is 55–60% pharmaceutical and biotech companies, 10–15% academic and research institutions, 5–10% hospitals, cancer centers and CROs, and 5% government, regulatory and industry organizations.
Stream 1 moves from first-in-class targets through translational modeling to resistance and the pipeline outlook. Each session gives you a natural opening line for a meeting later that day.
Cell therapy vendors should also note a Day 1 Stream 2 session in the next room: Biomarker Assays, Immune Profiling, CAR-T, TCR-T, and NK Cell Therapies for Solid Tumors or Analytical Strategies Supporting Cell Therapies (Priyanka Joshi, Associate Scientist, Obsidian Therapeutics). That overlap is why this works as a cancer immunotherapy conference in Boston for CDMOs, CROs and immune monitoring labs alike: the therapy teams and the people who measure what their therapies do share one floor. For a sense of who is building IO pipelines locally, see our guide to Boston oncology biotech companies.
The same two days work differently depending on what you sell. Plan your meetings around the sessions that match your offer.
Estimate what a set of pre-scheduled IO meetings is worth to your pipeline before you choose a package.
Run the ROI calculatorThe Boston agenda reserves three Platinum talk slots per stream on Day 1, three Gold slots per stream on Day 2 before lunch and three Silver slots per stream after lunch. Deciding early gives IO companies more time to plan their meetings and talk.
Stage time on Day 1, alongside the bispecific, translational modeling and IND readiness sessions, plus enough meetings to follow up with the people who heard you.
Exclusive to one company. The only package that speaks to both streams, for vendors who sell to IO program teams and biomarker teams at once.
Meetings without a booth or talk: a practical way to test the Boston market at a launch edition.
Full tier details are on the Boston sponsorship opportunities page, and the exclusive position is explained on the Boston headline sponsor page. Selling into the Stream 2 side too? See the Boston biomarker conference and Boston companion diagnostics conference pages. To compare editions, read the San Diego cancer immunotherapy conference page and the immuno-oncology summit series overview.
Tell us which IO functions you want to meet and we will recommend the right Stream 1 package.
Request the prospectusPick a package, add your own numbers and see the pipeline it creates. London 2026 sponsors averaged 15 to 25 meetings each, with 70% senior decision-makers in the room.
1. Choose a package
2. Your numbers
Year-one value of a new pharma or biotech customer
Booth visits, networking and questions after your talk
Share of conversations worth a proposal
Your typical close rate
Sponsorship plus travel and team costs
expected first-year revenue for every $1 of your event budget
Estimates only, based on the numbers you enter. Meetings and inclusions from the Boston 2027 sponsorship prospectus. 1:1 meetings are pre-scheduled with delegates you choose from the attendee list.
We will send your numbers to your inbox, ready to share with your team. Our sponsorship team gets a copy so they can answer questions.
The real London 2026 results, plus profiles of how different types of company use the 1:1 meetings, talks and stand to build pipeline.
What sponsors said
Here is what sponsors told us at our London 2026 launch edition.
We really liked the focus of the event, the topics, the talks, really good opportunity to engage with people, the support we get from you is really great and we appreciate that very much. Based on our experience we would be very interested in also sponsoring the next annual event.

We are always interested in sponsoring interesting conference, based on this years experience, I guess I will manage to get some budget for the next edition.

Conversations I have had are very high level, the footfalls been great and the kind of research going on around is really life changing. We will be very interested in sponsoring the second annual.

My experience here at Immunomark 2026 has been really great. We benefit from very good logistical organisation. Networking sessions were excellent and we consider Immunomark a strategic conference for the coming years.

We got the occasion to discuss customer projects and understand their needs better and how we can help them.

The conference has been great so far with strong interactions at the booth and excellent attendance at our talk. We will definitely think about the next edition.

Quality of the talks were really nice and the attendee list had experts from biotech pharma field. It was great meeting everyone and we look forward to positive outcomes.

The talks have been really interesting so far with a great combination of researchers and clinicians. Moderators encouraged excellent discussions.

Both. Stream 1 is dedicated to Immuno-Oncology, covering next-generation checkpoints, cell therapies for solid tumors, bispecific engagers, resistance and translational models. Stream 2 runs in parallel on Biomarkers & Companion Diagnostics. Your 1:1 meetings draw on the full delegate list across both streams.
The East Coast launch edition takes place in Boston in June 2027. Exact dates and the venue will be confirmed by the sponsorship team. It follows the San Diego edition (10–11 February 2027) and the London edition (3–4 March 2027).
The Boston Stream 1 faculty includes translational, computational, regulatory and clinical roles from companies such as AbbVie, Sanofi, AstraZeneca and Obsidian Therapeutics, and the agenda includes Translational Models Supporting IND Readiness. Meetings are chosen by you from the full delegate list and profiles, sent about 10 days before the event.
Yes. Platinum sponsors get a 30-minute Day 1 talk, Gold sponsors a 30-minute Day 2 pre-lunch talk and Silver sponsors a 15-minute Day 2 post-lunch talk, each in the stream you choose. The Headline sponsor gives a Day 1 morning keynote across both streams.
Boston is a launch edition, so the track record comes from London 2026: 300+ delegates from 100+ companies, 70% senior decision-makers, 200+ meetings, 15–25 meetings per sponsor and 55+ pre-scheduled 1:1s for title sponsors. Boston uses the same meeting model.
Tell us who you want to meet. We will send the prospectus and a package recommendation within one working day.